A promising biotechnology company developed a new approach that might treat a rare disease — but its sole employee didn’t do ...
CNN sits down with Ester Baiget, CEO of Novonesis, to discuss how biotechnology can boost food production in the Gulf.
Vir Biotechnology (VIR) said Sunday that its experimental combination treatment for chronic hepatitis delta met its primary goal in a phase 3 clinical trial, while separate phase 2 results showed ...
Many bioentrepreneurs incorrectly estimate the value of their technology by failing to account adequately for the cost, risk, ...
Vir Biotechnology (NASDAQ:VIR) said its combination treatment for chronic hepatitis delta met the primary and key secondary ...
Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. Read more on VIR ...
Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam ...
Sana Biotechnology, Inc. reported third-quarter 2026 financial results and business updates, highlighting progress toward clinical studies of its engineered cell therapy programs ...
Ended quarter with approximately $901 million in cash, cash equivalents and investments, excluding $90 million in upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results